Received: 11 October 2018
Accepted: 11 February 2019
First Online: 20 February 2019
Ethics approval and consent to participate
: The study was conducted according to the guidelines of the 1975 Declaration of Helsinki. Approval was obtained from the Institutional Ethics Committee from the participant Institutions (La Paz University Hospital and READE centre).
: All authors have read and approved the manuscript for publication.
: VN-C has received speaker fees and grants from Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB. DP-S has received grants and speaker fees from Pfizer, MSD, Abbvie, Novartis, Grifols and Menarini. CP-R has received grants and speaker fees from Pfizer and MSD. TR reports grants from Pfizer during the conduct of the study, grants from Genmab, consultancy fees from Genmab and payment for lectures from Pfizer, Abbvie and Regeneron outside the submitted work. GJW has received research funding from Pfizer and honoraria for lectures and in advisory boards of Pfizer, UCB, BMS, AbbVie, Novartis and Biogen. AB has received grants, consultancies and speaker fees from Abbvie, Pfizer, MSD, Roche, UCB, Celltrion, Novartis and Lilly. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.